公开(公告)号：US06312686B1

公开(公告)日：2001-11-06

申请号：US08648182

申请日：1997-12-23

Applicant: James Martin Staddon ,  Lee Laurence Rubin ,  Kurt Herrenknecht ,  Mary Louise Morgan

Inventor： James Martin Staddon ,  Lee Laurence Rubin ,  Kurt Herrenknecht ,  Mary Louise Morgan

IPC: A61K3324

CPC classification number: C12N9/00 ,  A61K31/00 ,  A61K31/285 ,  A61K33/24 ,  A61K45/06 ,  C12N9/99

Abstract: Permeability of the blood-brain barrier and other physiological barriers can be modulated by the degree of tyrosine phosphorylation of proteins. Agents which promote tyrosine protein dephosphorylation reduce the permeability of the blood-brain barrier and those which promote phosphorylation increase permeability. Increasing blood-brain barrier permeability is useful in delivering drugs having a desired effect upon the central nervous system; decreasing blood-brain barrier permeability and other physiological barrier permeability is useful in preventing undesired compounds reaching the CNS and in certain clinical conditions.

Abstract translation: 血脑屏障和其他生理屏障的渗透性可以通过蛋白质的酪氨酸磷酸化程度来调节。 促进酪氨酸蛋白去磷酸化的药物降低血脑屏障的渗透性，促进磷酸化的通路增加渗透性。 增加血脑屏障渗透性可用于将具有期望效果的药物递送至中枢神经系统; 降低血脑屏障通透性和其他生理屏障通透性可用于防止不想要的化合物到达CNS和某些临床条件。

公开(公告)号：US06407058B1

公开(公告)日：2002-06-18

申请号：US09280593

申请日：1999-03-29

Applicant: James Martin Staddon ,  Mary Louise Morgan ,  Marianne Jennifer Ratcliffe

Inventor： James Martin Staddon ,  Mary Louise Morgan ,  Marianne Jennifer Ratcliffe

IPC: A61K3800

CPC classification number: A61K38/1858 ,  A61K31/00 ,  A61K31/12 ,  A61K31/122 ,  A61K31/167 ,  A61K31/18 ,  A61K31/22 ,  A61K31/352 ,  A61K31/36 ,  A61K31/365 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/437 ,  A61K31/4741 ,  A61K31/496 ,  A61K31/55 ,  A61K31/553 ,  A61K38/105 ,  A61K38/1808

Abstract: The degree of phosphorylation of serine and threonine residues of p100/p120 can affect the permeability of physiological barriers and also cell—cell adhesion properties. By changing physiological levels, various disorders can be treated, including multiple sclerosis, cancer, head injuries, oedema, stroke, inflammation and gastric ulcers. Furthermore, drugs can be allowed to pass across physiological barriers and the barriers can then be closed.

Abstract translation: p100 / p120的丝氨酸和苏氨酸残基的磷酸化程度可以影响生理屏障的渗透性以及细胞粘附性。 通过改变生理水平，可以治疗各种疾病，包括多发性硬化，癌症，头部损伤，水肿，中风，炎症和胃溃疡。 此外，药物可以通过生理屏障，然后可以关闭屏障。

公开(公告)号：US06245888B1

公开(公告)日：2001-06-12

申请号：US08874197

申请日：1997-05-19

Applicant: James Martin Staddon

Inventor： James Martin Staddon

IPC: C07K100

CPC classification number: C07K14/4702

Abstract: A protein, p100, is disclosed having a molecular weight of about 100 kDa, being associated in vivo with catenin-cadherin complex of epithelial or endothelial cells, and having cross-reactivity with an antibody to the p120 protein involved in cell-cell adhesion. Also disclosed is a method to treat a cancer or developmental disorder characterized by compromised cell-cell adhesion.

Abstract translation: 公开了一种具有约100kDa分子量的蛋白质，其与体内与上皮细胞或内皮细胞的连环蛋白 - 钙粘蛋白复合物相关，并且与参与细胞粘附的p120蛋白的抗体具有交叉反应性。 还公开了一种治疗特征在于细胞 - 细胞粘附受损的癌症或发育障碍的方法。